GlassScriptPhysician profile
Heather B Schultz
NPI 1891982641
$1,504.66
in general payments reported to CMS, 2019-2025
20 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.73 · 2022: $451 · 2023: $338 · 2024: $312 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $915 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.26 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $292.59 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $253.96 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $129.42 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $112.95 | 2021-2024 | |
| Lilly USA, LLC | $87.84 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $83.66 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.10 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $60.00 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.35 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $51.72 | 2024 | Voquezna |
| Cranial Technologies, INC | $50.21 | 2024-2025 | Doc Band |
| Exact Sciences Corporation | $36.14 | 2023-2024 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $31.75 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.60 | 2022 | |
| Glaxosmithkline, LLC. | $28.26 | 2022-2025 | Trelegy Ellipta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.20 | 2023-2024 | Jardiance |
| Grifols USA, LLC | $26.83 | 2022 | |
| Dexcom, INC. | $25.84 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $19.35 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $14.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.